Almac Introduce Contained Drug Handling and Bottling Capabilities in EU and US Clinical Services Sites
July 2, 2013
Almac’s Clinical Services business unit has expanded its service offering for dispensing and bottling solid dosage products by introducing enhanced containment equipment and processes at its EU and US headquarters.
Managing Director of Almac Clinical Services, Dr Robert Dunlop commented, “In recent years we have experienced an increase in demand for facilities equipped to handle compounds of a higher potency. As a customer orientated company Almac saw an opportunity to meet the needs of its client base. This development at our European and North American Headquarters is the latest example of how Almac constantly strives to advance its service offering to reflect the needs of the drug development industry. “
Following successful installation and validation, the facilities are now operational and Almac welcome packaging discussions with companies who have potent products in their pipeline. For more information on Almac visit www.almacgroup.com
Notes to Editors:
The Almac Group provides a broad range of services from R&D, biomarker discovery and development, API manufacture, formulation development, clinical trial supply and IXRS® technology (IVRS/IWRS), to commercial-scale manufacture. Almac provides services to more than 600 companies, including all the world leaders in the pharmaceutical and biotech sectors.
The company employs over 3,300 individuals and is headquartered in Craigavon, Northern Ireland. US operations are based in Pennsylvania, North Carolina and California. Almac has now moved into its new North American Headquarters located in Souderton PA.